DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Azasite (Azithromycin Ophthalmic) - Published Studies

 
 



Azasite Related Published Studies

Well-designed clinical trials related to Azasite (Azithromycin Ophthalmic)

Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. [2011.01]

Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. [2010.11]

[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis] [2010.04]

Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. [2010.03]

Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions. [2009.11]

Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania. [2009.05]

Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. [2008.11]

Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis. [2008.11]

Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. [2008.06]

Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers. [2008.01]

Azithromycin prevents recurrence of severe trichiasis following trichiasis surgery: STAR trial. [2007.09]

Phase 3 Safety Comparisons for 1.0% Azithromycin in Polymeric Mucoadhesive Eye Drops versus 0.3% Tobramycin Eye Drops for Bacterial Conjunctivitis. [2007.08]

A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. [2007.06]

Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. [2007.05]

3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. [2007.04]

Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. [2006.03]

A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. [2005.10]

Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. [2003.04]

The efficacy of azithromycin in the treatment of acute infraorbital space infection. [2003.03]

Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. [2000.12]

Three-day course of oral azithromycin vs topical oxytetracycline/polymyxin in treatment of active endemic trachoma. [2000.07]

Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. [1999.12]

A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. [1997.03]

Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. [1996.05]

Effects of azithromycin on malariometric indices in The Gambia. [1995.09.30]

Randomised controlled trial of single-dose azithromycin in treatment of trachoma. [1993.08.21]

Well-designed clinical trials possibly related to Azasite (Azithromycin Ophthalmic)

Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. [2011.09]

Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. [2011.07]

Impact of Trichiasis surgery on physical functioning in Ethiopian patients: STAR trial. [2011.05]

Rates and risk factors for unfavorable outcomes 6 weeks after trichiasis surgery. [2011.04.25]

Trichiasis surgery in The Gambia: a 4-year prospective study. [2010.10]

Effect of trichiasis surgery on visual acuity outcomes in Ethiopia. [2009.11]

Surgery for Trichiasis, Antibiotics to prevent Recurrence (STAR) Clinical Trial methodology. [2005.08]

Other research related to Azasite (Azithromycin Ophthalmic)

Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. [2012]

Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis. [2012]

Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. [2012]

Toxicity comparison of intraocular azithromycin with and without a bioadhesive delivery system in rabbit eyes. [2011.11.09]

Effect of topical azithromycin on corneal innate immune responses. [2011.04.19]

Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. [2011.03]

[Combined pharmacological-surgical treatment in exudative age-related macular degeneration]. [2011]

AzaSite(R) inhibits Staphylococcus aureus and coagulase-negative Staphylococcus biofilm formation in vitro. [2010.12]

Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops. [2010.11.23]

Efficacy and safety of short-duration topical treatment with azithromycin oil-based eyedrops in an experimental model of corneal refractive surgery. [2010.11]

Mass treatment with azithromycin for trachoma control: participation clusters in households. [2010.10.05]

An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin. [2010.10]

New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system. [2010.09]

Pharmacokinetics of Azithromycin and Moxifloxacin in Human Conjunctiva and Aqueous Humor During and After the Approved Dosing Regimens. [2010.08.31]

Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. [2010.08]

Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. [2010.07]

Effect of oral azithromycin in the treatment of chlamydial conjunctivitis. [2010.06]

Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis. [2010.05.13]

Rapid, sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of topically applied azithromycin in rabbit conjunctiva tissues. [2010.05.01]

Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness. [2010.02]

[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis]. [Article in French] [2010]

Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. [2009.10]

Azithromycin reduces ocular infection during congenital transmission of toxoplasmosis in the Calomys callosus model. [2009.08]

Trimethoprim/Sulfamethoxazole and azithromycin combination therapy for ocular toxoplasmosis. [2009.07]

Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. [2009.07]

Lipid emulsions as a potential delivery system for ocular use of azithromycin. [2009.07]

Ocular pharmacokinetics of AzaSite Xtra-2% azithromycin formulated in a DuraSite delivery system. [2009.06]

Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. [2009.05]

Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. [2009.04]

[Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis] [2009]

Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. [2008.09]

Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. [2008.06]

Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. [2008.02]

An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite. [2007.12]

Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. [2007.09]

Trachoma control using the who adopted "safe with azithromycin". [2007.03]

Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali. [2007.01]

Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment. [2006.11]

Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year. [2006.08]

Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. [2005.11]

Effects of dehydration on corneal tissue absorption of topical azithromycin in rabbits. [2005.10]

Microbiological assay for the determination of azithromycin in ophthalmic solutions. [2005.06]

Mass treatment with single-dose azithromycin for trachoma. [2004.11.04]

Corneal pharmacokinetics of topically applied azithromycin and clarithromycin. [2004.10]

Other possibly related research studies

Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. [2008.06]

The impact of community level treatment and preventative interventions on trachoma prevalence in rural Ethiopia. [2008.06]

Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center. [2007.11]

Acute choroidal ischemia associated with toxoplasmic retinochoroiditis. [2007.09]

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. [2007.04]

[Chlamydial diseases of the eye. A short overview] [2007.01]

Bilateral acute anterior uveitis as a presenting symptom of Mycoplasma pneumoniae infection. [2006.10]

Can chlamydial conjunctivitis result from direct ejaculation into the eye? [2006.09]

[Stage-oriented treatment of Lyme borreliosis] [2006.06.22]

Interventions for trachoma trichiasis. [2006.07.19]

Mycobacterium chelonae keratitis after laser-assisted subepithelial keratectomy. [2006.06]

Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. [2006.01]

Tuberculosis. [2005.07]

Neonatal chlamydial infections: prevention and treatment. [2005]

Antibiotics for trachoma. [2005.04.18]

An index of community ocular Chlamydia trachomatis load for control of trachoma. [2005.03]

The effect of antibiotic treatment on active trachoma and ocular Chlamydia trachomatis infection. [2003.08]

Prevalence of trachoma in chronic conjunctivitis, Birjand, Islamic Republic of Iran. [2002.03]

Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. [2004.08.11]

Ophthalmomyiasis caused by the sheep bot fly Oestrus ovis in northern Iraq. [2004.08]

Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? [2003.05.15]

Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. [2003.04]

Current trachoma treatment methodologies: focus on advancements in drug therapy. [2002]

Antibiotics for trachoma. [2002]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014